TY  - BOOK
AU  - Balogun,Rasheed Abiodun
AU  - Abdel-Rahman,Emaad
AU  - Balogun,Seki A.
TI  - Chronic kidney disease: signssymptoms, management options and potential complications 
T2  - Nephrology research and clinical developments
SN  - 9781629485171
PY  - 2014///]
CY  - New York
PB  - Nova Science Publishers
KW  - Chronic renal failure
KW  - Kidneys
KW  - Diseases
KW  - Renal Insufficiency, Chronic
N1  - Includes bibliographical references and index; CHRONIC KIDNEY DISEASE SIGNS/SYMPTOMS, MANAGEMENT OPTIONS AND POTENTIAL COMPLICATIONS; CHRONIC KIDNEY DISEASE SIGNS/SYMPTOMS, MANAGEMENT OPTIONS AND POTENTIAL COMPLICATIONS; Library of Congress Cataloging-in-Publication Data; Contents; Preface; Section A: Chronic Kidney Disease in the General Population; Chapter I Signs and Symptoms of Chronic Kidney Disease; Abstract; 1. Introduction; 2. Definition; 3. Symptoms of CKD; 3.1. General Symptoms; 3.1.1. Anorexia; 3.1.2. Cachexia; 3.1.3. Malaise; 3.2. Cardiovascular; 3.3. Pulmonary; 3.4. Gastrointestinal; 3.5. Genitourinary; 3.6. Hematological; 3.7. Neurological3.7.1. Restless Leg Syndrome (RLS) and Periodic Limb Movement (PLM) disorder; 3.8. Skin; 3.9. Psychiatric; 4. Signs of CKD; References; Chapter II Complications of Chronic Kidney Disease; Abstract; 1. Anemia; Pathogenesis; i. Erythropoietin Deficiency; ii. Iron Deficiency; iii. Hepcidin; iv. Chronic Inflammation, Infections and Oxidative stress; v. Secondary Hyperparathyroidism; Incidence and Prevalence; Diagnosis; 2. Blood and Immune Disorders in Chronic Kidney Disease; 2.1. Bleeding Diathesis in Uremia; Pathogenesis; Clinical Manifestations; Diagnosis; 2.2. Heparin Induced ThrombocytopeniaIncidence; Pathogenesis; Clinical Manifestations; Diagnosis; 2.3. Thrombotic Events; 2.4. Immune Dysfunction in Uremia; 3. Cardiovascular Disease; Epidemiology; Risk Factors; i. Conventional Risk Factors; ia. Hypertension; ib. Diabetes Mellitus; ic. Dyslipidemia; id. Insulin Resistance; ie. Smoking; ii. Non-conventional Risk Factors; iia. Anemia; iib. Oxidative stress; iic. Inflammation; iid. Hyperhomocysteinemia and endothelial dysfunction; iie. Advanced Glycation End Products; iii. Other Risk Factors; Clinical Manifestations; Diagnosis; 4. Bone and Mineral Metabolism in CKDPathogenesis; a. High Turnover Bone Disease; Abnormalities of Calcium Homeostasis; Abnormalities in Phosphate Homeostasis; Abnormalities of Vitamin D Homeostasis; Clinical Manifestations of High Turnover Bone Disease; b. Low Turnover Bone Disease; Diagnosis of Renal Bone Disease; 5. Acid Base Disturbances in CKD; Pathogenesis; Uremic Acidosis and Nutritional status; Uremic Acidosis and Renal Osteodystrophy; Uremic Acidosis and Cardiovascular Disease; 6. Neuropsychological Manifestations in Chronic Kidney Disease; 6.1. Uremic Encephalopathy; Pathogenesis; Clinical ManifestationsDiagnosis; 6.2. Peripheral Neuropathy; Mononeuropathy; Polyneuropathy; 6.3. Autonomic Neuropathy; 6.4. Neurologic Syndromes Associated with Renal Replacement Therapy; Dialysis Disequilibrium Syndrome; Dialysis Encephalopathy; Restless Leg Syndrome; 6.5. Sleep Disorders; Sleep Disordered Breathing (SDB) and Obstructive Sleep Apnea (OSA); Excessive Daytime Sleepiness (EDS); 6.6. Psychological Manifestations; References; Chapter III Treatment of Chronic Kidney Disease Complications; Abstract; I. Anemia; Historical Background; Erythropoiesis Stimulating Agents (ESAs)
N2  - Chronic kidney disease is a non-communicable disease that has experienced a global surge in incidence and prevalence over the past few decades, and it has been increasingly considered a major contributor to the global disease burden and mortality. In prior years, most of the awareness and treatment of patients with chronic kidney disease, particularly in the developed world, had focused on patients with end stage renal disease, one of the potential outcomes of chronic kidney disease. More recent epidemiological data has shown that the majority of the burden of chronic kidney disease occurs in
UR  - #gotoholdings
ER  -